



ASX/Media Release

26 November 2015

Strong rebound by Monash IVF Group in the four months to October 2015

Monash IVF Group (ASX: MVF), a leading provider and driving force in fertility care, women's imaging and diagnostics in Australia and Malaysia, today provided a market update at its Annual General Meeting of shareholders.

As announced in August this year and detailed at its AGM today, Monash IVF Group reported a 9.6% lift in Group revenues to \$125 million and normalised net profit after tax (NPAT) of \$23.3 million for the year ended 30 June 2015 against the previous corresponding period (pcp).

In the first quarter of FY16 (Q1FY16), MVF is seeing a strong rebound in long-term Assisted Reproductive Services (ARS) market growth rates and corresponding uplift in the Group's revenues and total patient treatments for the quarter.

At its AGM today MVF detailed the following:

- MVF total patient treatments grew by 18.5% in the four months to October 15 on the pcp, whilst domestic key markets patient treatments in which MVF operates are 5.6% up on a comparable basis;
- Total ARS market share in the markets in which Monash IVF operates are up to 41.3% versus 39.8% in pcp. In particular, MVF recorded above industry growth rates in Victoria, South Australia and Queensland;
- Total Australia ARS market share increased to 24.0% from 21.9% in pcp;
- Recently acquired businesses – Monash IVF Bondi Junction and Sydney Ultrasound for Women – advanced integration and broadening our existing NSW footprint.
- BUMP IVF clinic in Sydney continues to build strong momentum; and
- KL Fertility in Malaysia is delivering growth whilst building clinic capacity to accommodate further organic growth.

As a result of the underlying growth in the overall market, improvement in market share and the impact of the acquisitions into the Monash IVF Group in FY2015, and subject to

trading in the remaining months, we anticipate the reported NPAT for H1FY2016 will be approximately 25% up on the previous corresponding period.

Chief Executive Officer James Thiedeman said: “Monash IVF has enjoyed a strong rebound in patient treatments and associated revenues in Q1FY16.

Our strategy of building on our heritage of scientific excellence and clinical innovation underpins everything we do. Coupled with the most experienced and talented doctor network in the ARS field in Australia and Malaysia, this enables us to provide our patients with the highest chance of pregnancy success and appropriate treatment.

In FY16, Monash IVF continues to focus on three key areas for growth and performance; to continue to leverage its heritage of scientific and technological excellence to maintain leading pregnancy success rates in the industry; further develop its low intervention offering; and continue to capture growth through further acquisition opportunities in Australia and Asia.”

-ENDS-

Investor Enquiries:

James Thiedeman
Chief Executive Officer
Monash IVF Group
+61 3 9452 8235

Michael Knaap
Chief Financial Officer
Monash IVF Group
+61 3 9452 8235

Media enquiries:

Justin Kirkwood
+61 2 9231 5600
+61 411 251 324
Justin@kirkwoods.com.au

About Monash IVF Group

Monash IVF Group is a leading provider of assisted reproductive services and specialist womens imaging and diagnostic services in Australia and Malaysia. The Group is a driving force in the development of assisted reproductive technologies and has many Australian and world firsts since the work of our pioneers who achieved the first IVF pregnancy in the world in 1973.